|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, July 29, 2017 ) Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Interleukin-1 receptor-associated kinase 4 (IRAK-4) is a protein kinase involved in signaling innate immune responses from Toll-like receptors. Mutations in IRAK-4 result in IRAK4 deficiency and recurrent invasive pneumococcal disease. It phosphorylates E3 ubiquitin ligases Pellino proteins to promote pellino-mediated polyubiquitination of IRAK1. Ubiquitin-binding domain of IKBKG/NEMO binds to polyubiquitinated IRAK1 bringing together the IRAK1-MAP3K7/TAK1-TRAF6 complex and the NEMO-IKKA-IKKB complex. MAP3K7/TAK1 activates IKKs leading to NF-kappa-B nuclear translocation and activation.
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) pipeline Target constitutes close to 15 molecules. Out of which approximately 15 molecules are developed by Companies. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 11 and 2 respectively. Report covers products from therapy areas Immunology, Musculoskeletal Disorders, Oncology, Genito Urinary System And Sex Hormones and Women's Health which include indications Rheumatoid Arthritis, Inflammation, Gouty Arthritis (Gout) , Psoriasis, Diffuse Large B-Cell Lymphoma, Autoimmune Disorders, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) , Arthritis, Blood Cancer, Chronic Kidney Disease (Chronic Renal Failure) , Endometriosis, Hematological Tumor, Systemic Lupus Erythematosus and Waldenstrom Macroglobulinemia.
The latest report Interleukin 1 Receptor Associated Kinase 4 - Pipeline Review, H2 2017, outlays comprehensive information on the Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type. It also reviews key players involved in Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
For more information about this report at http://www.reportsweb.com/interleukin-1-receptor-associated-kinase-4-pipeline-review-h2-2017
Report Scope
- The report provides a snapshot of the global therapeutic landscape for Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1)
- The report reviews Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001884175/sample
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Company profiles
Amgen Inc
Astellas Pharma Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
Bayer AG
Beijing Hanmi Pharmaceutical Co Ltd
Genentech Inc
Merck & Co Inc
Pfizer Inc
Rigel Pharmaceuticals Inc
TG Therapeutics Inc
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001884175/discount
List of Tables
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indication, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1) , H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Amgen Inc, H2 2017
Pipeline by Astellas Pharma Inc, H2 2017
Pipeline by AstraZeneca Plc, H2 2017
Pipeline by Aurigene Discovery Technologies Ltd, H2 2017
Pipeline by Bayer AG, H2 2017
Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2017
Pipeline by Genentech Inc, H2 2017
Pipeline by Merck & Co Inc, H2 2017
Pipeline by Pfizer Inc, H2 2017
Pipeline by Rigel Pharmaceuticals Inc, H2 2017
Pipeline by TG Therapeutics Inc, H2 2017
Dormant Projects, H2 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001884175/buy/3500
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
